The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Levraud, J. P.
Right arrow Articles by Kourilsky, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Levraud, J. P.
Right arrow Articles by Kourilsky, P.

The Journal of Immunology, Vol 158, Issue 7 3335-3343, Copyright © 1997 by American Association of Immunologists

ARTICLES

IL-2 gene delivery within an established murine tumor causes its regression without proliferation of preexisting antitumor-specific CTL

JP Levraud, MT Duffour, L Cordier, M Perricaudet, H Haddada and P Kourilsky
Gene Molecular Biology Unit, INSERM Unit 277, Pasteur Institute, Paris, France. jlevraud@pasteur.fr

Regression of P815 tumors established on naive syngeneic mice can be obtained by the intratumoral injection of a single dose of an adenoviral vector expressing the IL-2 gene (Ad.IL2). Injection triggers local IL-2 production for at least 10 days. We measured a number of immunologic parameters in situ following intratumoral Ad.IL2 treatment. We also analyzed the situation of regression obtained upon challenge with P815 cells of mice previously immunized against the tumor and compared both systems. While IFN-gamma messenger RNA expression was found to be elevated in both situations of tumor regression, the level of infiltration by tumor-specific CTL was different. A small amount of tumor-specific CD8+ T cells were present in growing, untreated tumors. Such cells are found in much larger numbers in tumors rejected upon challenge, consistent with a CTL-mediated rejection. In contrast, they were found not to proliferate following Ad.IL2 injection. The latter caused an increased infiltration of a polyclonal, presumably nonspecific, T cell population. These results suggest that the initial regression of established P815 tumors following Ad.IL2 treatment in vivo is mostly due to nonspecific effectors.


This article has been cited by other articles:


Home page
 J. Immunol.Home page
C. Jackaman, C. S. Bundell, B. F. Kinnear, A. M. Smith, P. Filion, D. van Hagen, B. W. S. Robinson, and D. J. Nelson
IL-2 Intratumoral Immunotherapy Enhances CD8+ T Cells That Mediate Destruction of Tumor Cells and Tumor-Associated Vasculature: A Novel Mechanism for IL-2
J. Immunol., November 15, 2003; 171(10): 5051 - 5063.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. C. Fernandez, J.-P. Levraud, H. Haddada, M. Perricaudet, and P. Kourilsky
High Frequency of Specific CD8+ T Cells in the Tumor and Blood Is Associated with Efficient Local IL-12 Gene Therapy of Cancer
J. Immunol., January 1, 1999; 162(1): 609 - 617.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. thor Straten, P. Guldberg, T. Seremet, R. A. Reisfeld, J. Zeuthen, and J. C. Becker
Activation of preexisting T cell clones by targeted interleukin 2 therapy
PNAS, July 21, 1998; 95(15): 8785 - 8790.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Muller, D. H. Margolin, P. L. Nara, W. G. Alvord, and H. Kohler
Stimulation of HIV-1-neutralizing antibodies in simian HIV-IIIB-infected macaques
PNAS, January 6, 1998; 95(1): 276 - 281.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1997 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1997 by The American Association of Immunologists, Inc. All rights reserved.